EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of Omadacycline in community-acquired pneumonia among elderly patients: a real-world evidence study

Xinran Xie, Jiayu Deng, Gengyuan Sun, Yanqing Song

Frontiers in Cellular and Infection Microbiology · 31.07.2026 · 16

DOI: 10.3389/fcimb.2026.1875598 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 31.07.2026. Verfasst von Xinran Xie und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Community-Acquired Pneumonia, Anti-Bacterial Agents, Tetracyclines, Community-Acquired Infections. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to evaluate real-world effectiveness and safety of omadacycline for elderly community-acquired pneumonia (CAP) versus tigecycline, moxifloxacin, and cefoperazone-sulbactam after inverse probability of treatment weighting (IPTW).

Methods

This single-center retrospective cohort study enrolled non-ICU hospitalized elderly CAP patients. Missing covariates were handled by multiple imputation, and IPTW balanced groups. Primary outcome was pragmatic clinical response (improvement in at least one of laboratory markers, chest imaging, or clinical symptoms), with a sensitivity analysis requiring all three. Secondary outcomes included hospital stay, antibiotic duration, microbiological clearance, and adverse events. Subgroup analyses used age < 75 vs ≥ 75 years and CURB-65 < 2 vs ≥ 2.

Results

A total of 1,208 patients were included: 177 in the omadacycline group, 124 in the tigecycline group, 666 in the moxifloxacin group, and 241 in the cefoperazone-sulbactam group. After IPTW adjustment, omadacycline showed a pragmatic clinical response comparable to tigecycline, higher than moxifloxacin, but lower than cefoperazone-sulbactam. Omadacycline was associated with shorter hospital stay than tigecycline and cefoperazone-sulbactam, but longer than moxifloxacin; antibiotic duration was comparable to tigecycline, shorter than cefoperazone-sulbactam, but longer than moxifloxacin. Microbiological clearance was lower with omadacycline in the evaluable subset, whereas recorded adverse events were fewer but limited by rare-event sparsity. Exploratory subgroup analyses suggested that cefoperazone-sulbactam had a higher response than omadacycline in patients aged <75 years or with CURB-65 <2. Subgroup analyses suggested heterogeneous associations by age and disease severity and should be interpreted as exploratory.

Conclusion

In this real-world analysis of elderly patients with CAP after IPTW adjustment, omadacycline showed a pragmatic clinical response comparable to tigecycline, higher than moxifloxacin, but lower than cefoperazone-sulbactam. Omadacycline was associated with shorter hospital stay than tigecycline and cefoperazone-sulbactam, but longer hospital stay than moxifloxacin. Antibiotic duration was comparable to tigecycline, shorter than cefoperazone-sulbactam, but longer than moxifloxacin. Given the broad pragmatic endpoint, high baseline response rate, sensitivity to endpoint definition and missing-data handling, incomplete microbiological follow-up, and residual confounding inherent to retrospective data, these findings should be interpreted as exploratory and require prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Community-Acquired PneumoniaAnti-Bacterial AgentsTetracyclinesCommunity-Acquired InfectionsHumansFemaleRetrospective StudiesAged, 80 and overTreatment OutcomeAgedMaleMoxifloxacinTigecyclineSulbactamCefoperazoneLength of Stay

Stichwörter der Autor:innen

community-acquired pneumoniaelderly patientsimmunocompromised individualsinverse probability of treatment weightingomadacyclinereal-world study

Substanzen

Anti-Bacterial AgentsomadacyclineTetracyclinesMoxifloxacinTigecyclineSulbactamCefoperazone

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Jilin University, Changchun, China.
  • Department of Pharmacy of Lequn Branch, The First Hospital of Jilin University, Changchun, China.

Zitieren

APA

Xie, X., Deng, J., Sun, G., & Song, Y. (2026). Efficacy and safety of Omadacycline in community-acquired pneumonia among elderly patients: a real-world evidence study. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1875598

Vancouver

Xie X, Deng J, Sun G, Song Y. Efficacy and safety of Omadacycline in community-acquired pneumonia among elderly patients: a real-world evidence study. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1875598

BibTeX
@article{Xie2026,
  author = {Xie, Xinran and Deng, Jiayu and Sun, Gengyuan and Song, Yanqing},
  title = {Efficacy and safety of Omadacycline in community-acquired pneumonia among elderly patients: a real-world evidence study},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fcimb.2026.1875598}
}
Kostenlos starten →